In this issue of Hematology/Oncology Clinics, guest editor Dr. P. Leif Bergsagel brings his considerable expertise to the topic of New Developments in Myeloma. With the advent of next generation sequencing and immune profiling technologies, marked advances have been made recently in the understanding of the molecular and immune pathogenesis of multiple myeloma. Yet even with these advances, there is a continual search for new therapeutic approaches. In this issue, top experts discuss a full range of clinically relevant topics in this complex and fast-changing field.
1. Cover image - p. i 2. Title page - p. i 3. Table of Contents - p. i 4. Copyright - p. ii 5. Contributors - p. iii 6. Forthcoming Issues - p. xii 7. Preface - p. xiii 8. Dedication - p. xvii 9. Molecular Pathogenesis of Multiple Myeloma: Clinical Implications - p. 267 10. Immune-Pathogenesis of Myeloma - p. 281 11. Smoldering Multiple Myeloma: Observation Versus Control Versus Cure - p. 293 12. Cereblon-Targeting Ligase Degraders in Myeloma: Mechanisms of Action and Resistance - p. 305 13. Proteasome Inhibitors in Multiple Myeloma: Biological Insights on Mechanisms of Action or Resistance Informed by Functional Genomics - p. 321 14. Monoclonal Antibodies in the Treatment of Multiple Myeloma - p. 337 15. Bispecific Antibodies in the Treatment of Multiple Myeloma - p. 361 16. Chimeric Antigen Receptor T Cells in the Treatment of Multiple Myeloma - p. 383 17. Is There Still a Role for Stem Cell Transplantation in Multiple Myeloma? - p. 407 18. Role of Consolidation and Maintenance - p. 421 19. Management of Newly Diagnosed Multiple Myeloma Today, and in the Future - p. 441 20. Impact of Clonal Heterogeneity in Multiple Myeloma - p. 461 21. Measurable Residual Disease and Decision-Making in Multiple Myeloma - p. 477 22. Approach to High-Risk Multiple Myeloma - p. 497 23. New Therapies on the Horizon for Relapsed Refractory Multiple Myeloma - p. 511 24. Immunocompetent Mouse Models of Multiple Myeloma: Therapeutic Implications - p. 533
In this issue of Hematology/Oncology Clinics, guest editor Dr. P. Leif Bergsagel brings his considerable expertise to the topic of New Developments in Myeloma. With the advent of next generation sequencing and immune profiling technologies, marked advances have been made recently in the understanding of the molecular and immune pathogenesis of multiple myeloma. Yet even with these advances, there is a continual search for new therapeutic approaches. In this issue, top experts discuss a full range of clinically relevant topics in this complex and fast-changing field.
1. Cover image - p. i 2. Title page - p. i 3. Table of Contents - p. i 4. Copyright - p. ii 5. Contributors - p. iii 6. Forthcoming Issues - p. xii 7. Preface - p. xiii 8. Dedication - p. xvii 9. Molecular Pathogenesis of Multiple Myeloma: Clinical Implications - p. 267 10. Immune-Pathogenesis of Myeloma - p. 281 11. Smoldering Multiple Myeloma: Observation Versus Control Versus Cure - p. 293 12. Cereblon-Targeting Ligase Degraders in Myeloma: Mechanisms of Action and Resistance - p. 305 13. Proteasome Inhibitors in Multiple Myeloma: Biological Insights on Mechanisms of Action or Resistance Informed by Functional Genomics - p. 321 14. Monoclonal Antibodies in the Treatment of Multiple Myeloma - p. 337 15. Bispecific Antibodies in the Treatment of Multiple Myeloma - p. 361 16. Chimeric Antigen Receptor T Cells in the Treatment of Multiple Myeloma - p. 383 17. Is There Still a Role for Stem Cell Transplantation in Multiple Myeloma? - p. 407 18. Role of Consolidation and Maintenance - p. 421 19. Management of Newly Diagnosed Multiple Myeloma Today, and in the Future - p. 441 20. Impact of Clonal Heterogeneity in Multiple Myeloma - p. 461 21. Measurable Residual Disease and Decision-Making in Multiple Myeloma - p. 477 22. Approach to High-Risk Multiple Myeloma - p. 497 23. New Therapies on the Horizon for Relapsed Refractory Multiple Myeloma - p. 511 24. Immunocompetent Mouse Models of Multiple Myeloma: Therapeutic Implications - p. 533
